Combination Antibiotic Zerbaxa Approved

Combination Antibiotic Zerbaxa Approved

Combination Antibiotic Zerbaxa Approved

Sanctioned for complicated abdominal, urinary tract infections

MONDAY, Dec. 22, 2014 (HealthDay News) -- The combination antibiotic Zerbaxa (ceftolozane/tazobactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated abdominal infections and complicated urinary tract infections.

The approval for abdominal infections was approved in combination with another drug, metronidazole, the agency said in news release. The approval for urinary tract infection includes infection of the kidney.

Zerbaxa is the fourth antibiotic to be FDA-approved in 2014, following approval of Dalvance (dalbavancin), Sivextro (tedizolid) and Orbactiv (oritavancin).

The drug's label includes a warning about decreased effectiveness among people with kidney impairment, the FDA said. The most common side effects reported during clinical testing included nausea, diarrhea, headache and fever.

Zerbaxa is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.

More information

To learn more, visit the FDA.
Copyright © 2014 HealthDay. All rights reserved.